| Title |
Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients
|
|---|---|
| Published in |
Targeted Oncology, November 2013
|
| DOI | 10.1007/s11523-013-0300-y |
| Pubmed ID | |
| Authors |
Minghui Zhang, Xiaosan Zhang, Shu Zhao, Yan Wang, Wenyu Di, Gangling Zhao, Maopeng Yang, Qingyuan Zhang |
| Abstract |
Triple-negative breast cancer (TNBC) is a particular type of breast cancer which is characterized by its biological aggressiveness, worse prognosis, and lack of prognostic markers or therapeutic targets in contrast with hormonal receptor-positive and human epidermal growth factor receptor 2-positive (HER2+) breast cancers. We aimed to evaluate survivin and epidermal growth factor receptor (EGFR) expression and their prognostic value and determine their relationships with the clinicopathological parameters of TNBC. A total of 136 patients who had undergone a resection of primary TNBC were enrolled at the Third Affiliated Hospital of Harbin Medical University from March 2003 to September 2005. Expression of ER, PR, HER2, EGFR, and survivin was assessed by immunohistochemistry. The association of TNBC and other clinicopathological variables and the prognostic value of survivin and EGFR expression were evaluated. Survivin was expressed in 62 (45.6 %) cases and EGFR was expressed in 82 (60.3 %) cases. Survivin expression was associated with menopausal status (P = 0.011), tumor size (P = 0.037), and lymph node status (P = 0.001). EGFR expression was associated with menopausal status (P = 0.029), lymph node status (P = 0.004), P53 expression (P = 0.001), Ki-67 expression (P = 0.028), and lymphatic vascular invasion (P = 0.037). A multivariate analysis demonstrated that tumor size (hazard ratio (HR) 1.587, 95 % confidence interval (CI) 1.081-2.330, P = 0.018 for disease-free survival (DFS); HR 1.606, 95%CI 1.096-2.354, P = 0.015 for overall survival (OS)), lymph node status (HR 2.873, 95%CI 1.544-5.344, P = 0.001 for DFS; HR 2.915, 95%CI 1.553-5.471, P = 0.001 for OS), tumor grade (HR 1.914, 95%CI 1.218-3.007, P = 0.005 for DFS; HR 1.983, 95%CI 1.228-3.203, P = 0.005 for OS), EGFR (HR 3.008, 95%CI 1.331-6.792, P = 0.008 for DFS; HR 3.151, 95%CI 1.374-7.226, P = 0.007 for OS), and survivin (HR 1.573, 95%CI 1.087-2.277, P = 0.016 for DFS; HR 1.607, 95%CI 1.088-2.374, P = 0.017 for OS) were of prognostic significance for disease-free and overall survival. We draw a conclusion from the present study that survivin and EGFR expression are useful prognostic markers of TNBC and might be useful for molecular targeting therapy of TNBC treatment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 70 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 17% |
| Student > Master | 9 | 13% |
| Student > Ph. D. Student | 8 | 11% |
| Other | 7 | 10% |
| Student > Bachelor | 4 | 6% |
| Other | 8 | 11% |
| Unknown | 22 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 21% |
| Biochemistry, Genetics and Molecular Biology | 10 | 14% |
| Immunology and Microbiology | 6 | 9% |
| Agricultural and Biological Sciences | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 7 | 10% |
| Unknown | 25 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2013.
All research outputs
#17,704,678
of 22,733,113 outputs
Outputs from Targeted Oncology
#318
of 548 outputs
Outputs of similar age
#150,758
of 211,402 outputs
Outputs of similar age from Targeted Oncology
#3
of 5 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 548 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 211,402 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.